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NOTES FROM THE FIELD 
 Expressway to Cancer Clinical Trials: Reducing Administrative Barriers to Enrollment 
Audra Putt, MPH, CPH, Michigan Department of Health and Human Services 
For nearly 20 years, the Michigan Cancer Consortium (MCC) has been involved in 
efforts with a variety of stakeholders to increase cancer patient participation in clinical trials. In 
2001, the MCC partnered with the Michigan Working Group to Improve Cancer Outcomes on 
the development of the Consensus Guidelines for Healthcare Coverage of Routine Patient Care 
Cost Associated with Oncology Clinical Trials. The goal of this Consensus Agreement’s creation 
was to increase participation in specific cancer-related clinical trials by supporting the 
predictability of payment for clinical trial services. The voluntary Consensus Agreement includes 
a framework detailing third party payer coverage of patient costs in relation to their benefit plan 
for clinical trial enrollment. Members of the Michigan Association of Health Plans supported the 
Consensus Agreement and agreed to increase participation in cancer-related clinical trials 
through coverage of routine costs associated with participation. A 2015 assessment supported by 
the MCC found clinical trial coverage through larger Michigan health plans (including Medicaid 
and Medicare) generally aligns with the Consensus Agreement.  
 
With changes related to health care coverage through the Affordable Care Act and 
advancements in treatment, the MCC Board of Directors selected increasing cancer clinical trial 
enrollment as the 2016-2017 priority under the Cancer Plan for Michigan’s Diagnosis and 
Treatment Goal in 2016. The MCC Clinical Trials Priority Workgroup was tasked with 
developing a project to support this effort. The workgroup convened with the goal to ensure 
Michigan residents with cancer who want to join a clinical trial can do so with fewer barriers. In 
2016, 7 percent of Michigan adults who reported a cancer diagnosis also reported participating in 
cancer treatment clinical trials (Michigan Department of Health and Human Services, 2016).  
 
The workgroup began by surveying stakeholders with the MCC and Michigan Society of 
Hematology and Oncology (MSHO) to assess barriers to clinical trial enrollment. Survey results 
indicated that providers had concerns with the sometimes-lengthy clinical trial enrollment 
process. As a result, the workgroup decided their project would address prior authorization 
concerns. Insurers often require prior authorization for cancer clinical trial enrollment, and ask 
for different pieces of information. This can lead to communication barriers between providers 
and insurers. In some instances, patient enrollment can be delayed by weeks while prior 
authorization is approved. The workgroup project focused on facilitating more rapid response to 
prior authorization requests by creating a fax cover sheet that could be shared with practitioners 
and used as a “heads up” when enrolling patients in cancer clinical trials. 
The fax cover sheet was created for use when a health insurance carrier requires prior 
authorization for participation in a cancer clinical trial. It asks for such information as why the 
patient is eligible to participate, the therapeutic purpose for conducting the trial, and whether the 
trial is federally funded (see Appendix A for the fax cover sheet). Use of the fax cover sheet 
intends to simplify the prior authorization process and reduce the time needed to prepare and 
receive approval for authorization, thus decreasing the administrative burden for providers and 
insurers. The MCC Board of Directors approved the fax cover sheet in August 2016 and made it 
available as a fillable form on the MCC Website.   
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After development of the fax cover sheet, the workgroup established a promotion plan for 
sharing it with various stakeholders and partners. Steps were taken to promote the fax cover 
sheet at the MCC Annual Meeting, on the MCC Website, at hospital cancer committee meetings, 
and with partner newsletters. Following promotion, an evaluation plan for determining the cover 
sheet’s reach was also established. In 2017, it was downloaded from the MCC website 261 times. 
Questions about knowledge and use of the fax cover sheet were included in the 2017 MCC 
Annual Survey. MSHO members were also surveyed on similar questions in the fall of 2017. 
The results from both surveys (Figure 1) indicated there is still work to be done with promoting 
the fax cover sheet.  
 Michigan Cancer Consortium 
Member Survey 
Michigan Society of 
Hematology and Oncology 
Member Survey 
Number of respondents (N=) 86 111 
Aware of the cover sheet 23 (26.7%) 21 (18.9%) 
Used the cover sheet in their 
office 
3 (3.5%) 12 (10.9%) 
Figure 1. Partner Knowledge and Use of the Clinical Trials Fax Cover Sheet Form 
 
Over the next two years, the workgroup will continue to promote cancer clinical trial 
enrollment. A new project will be undertaken by the workgroup to develop infographics for 
patients and primary care providers, detailing the benefits of clinical trial enrollment. To support 
health equity, the infographics will meet accessibility guidelines. The MCC and Clinical Trials 
Priority Workgroup will remain dedicated to providing support and resources to increase the 
number of Michigan adults with cancer who participate in cancer clinical trials.  
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Appendix A: MCC Clinical Trials Cover Sheet 
 
 
  
